COMMUNIQUÉS West-GlobeNewswire

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
25/06/2026
Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 – [...]
Press Release: Sanofi Foundation opens new chapter centered on future generations
25/06/2026
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those [...]
Communiqué de presse : La Fondation Sanofi ouvre un nouveau chapitre centré sur les générations futures
25/06/2026
La Fondation Sanofi ouvre un nouveau chapitre centré sur les générations futures Paris, 25 juin 2026 . La Fondation Sanofi ouvre un nouveau chapitre avec un engagement renforcé en faveur des enfants et des jeunes, en [...]
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
25/06/2026
Brings more than 25 years of global drug development, regulatory and strategic leadership experience successfully guiding innovative therapies from clinical development through regulatory approval and commercialization [...]
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
25/06/2026
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
25/06/2026
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral [...]
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
25/06/2026
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global [...]
TWL Introduces Virtual Tirzepatide Assessment Program for Eligible Weight-Management Patients
25/06/2026
New digital-care process connects clinical evaluation, coverage assistance, pharmacy coordination and continuing provider support New York, NY, June 24, 2026 (GLOBE NEWSWIRE) -- TWL today announced the introduction of a [...]
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
25/06/2026
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced [...]
FitRx Introduces Streamlined Tirzepatide Evaluation and Care Program
25/06/2026
New virtual-care process coordinates medical review, prescription support, insurance navigation and ongoing follow-up for eligible weight-management patients New York, NY, June 24, 2026 (GLOBE NEWSWIRE) -- FitRx [...]
Breckenridge Distillery Rum Cask Finish Awarded Highest Honor at San Francisco World Spirits Competition
24/06/2026
Honey Whiskey Also Earns Gold, Reinforcing Breckenridge Distillery’s Global Recognition BRECKENRIDGE, Colo., June 24, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most-awarded craft distilleries in the U [...]
Jushi Holdings Inc. Announces Voting Results of Annual General and Special Shareholders’ Meeting
24/06/2026
BOCA RATON, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: JUSHF ) , a vertically integrated, multi-state cannabis operator, announces the voting results of [...]
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
24/06/2026
TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based [...]
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
24/06/2026
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company [...]
Modern Therapy Group launches virtual intensive outpatient program for mental health
25/06/2026
Structured, clinician-led care for clients who need more than weekly therapy New York, NY, June 24, 2026 (GLOBE NEWSWIRE) -- Modern Therapy Group has launched a virtual intensive outpatient program (IOP) for adults [...]
Cosmos Health’s C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin
24/06/2026
CHICAGO, June 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided an update on the growing [...]
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
24/06/2026
FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Passage Bio and Remix Therapeutics Announce Merger Agreement
24/06/2026
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM [...]
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
24/06/2026
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]

Pages